Sponsors and exhibitors


Basel is the most dynamic economic region in Switzerland and one of the most productive and innovative locations worldwide. Global leaders in the life sciences industry – Novartis, Roche, Syngenta, Lonza and others – have their headquarters in the Basel region. Basel is considered one of Europe’s top locations for life sciences and healthcare. This stimulating environment has given rise to a plethora of innovative research firms, including in the medical and biotechnology fields.

REPAIR Impact Fund

Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.

The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects, which is anticipated to yield at least one new therapy reaching the market.

The REPAIR Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs. Our philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities.

REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.


BioVersys AG focuses on life threatening infectious diseases. As a privately owned clinical stage Swiss biopharmaceutical company working on research & development of small molecules acting on novel bacterial targets, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (BVL-GSK098, Phase 2a) in collaboration with GSK and a consortium of the University of Lille.


INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, diagnostics and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).

NCCR AntiResist

The National Center of Competence in Research AntiResist aims to bring about a paradigm shift in antibiotic research with an interdisciplinary approach that assembles a Swiss-wide network of research groups from the fields of clinical research, biology, chemistry, computation, engineering and pharmacology.

The research program is structured into three four-year phases covering strategically and dynamically evolving milestones. Research activities center around a better understanding of pathogen physiology in patients; developing axenic and tissue-based model systems mimicking patient environments; and engineering of novel screening platforms for the next generation of antibiotics.

NCCR AntiResist is funded by the Swiss National Science Foundation, and is based in the Biozentrum at its home institution of the University of Basel.

Innovate UK

We are the UK’s innovation agency. We help UK businesses to grow through the development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.

We help companies, through three strands of activity:
– inspire: to make the opportunity visible and compelling
– involve: to bring relevant organisations and people together
– invest: to convene the resources needed, including our own.

We do this in our five strategic theme areas and through the six strong foundations that underpin all our activities.


The Global Antibiotic Research & Development Partnership (GARDP) develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and expands access to them. It puts public health needs at the centre of antibiotic drug development to address the immediate crisis of antimicrobial resistance (AMR). Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.


Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.   

Selvita was established in 2007 and currently employs over 1000 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia. 

Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. If you want to learn more about our services, visit our website.

Leibniz Health Technologies

A Research Alliance of the Leibniz Association

Providing technological solutions for unmet medical needs − this is the main focus of the 19 members of the interdisciplinary research alliance Leibniz Health Technologies (LHT).

To battle antimicrobial resistances, 16 Leibniz institutes and 3 spin-off companies are cooperating in interdisciplinary competence areas like Plasma Medicine, Point-of-Care Technologies or Bioactive Materials.

LHT’s impactful technologies in the AMR domain include rapid point-of-care testing devices that utilize biophotonics and molecular assays. The Leibniz partners of the alliance also develop new antimicrobial biomaterials and coatings and create innovative spore-killing disinfectants. Furthermore, LHT partners are actively developing therapeutic systems for cold atmospheric plasma treatments to enhance wound healing and combat pathogens.


Basilea Pharmaceutica

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. The company has successfully developed and launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, Basilea has preclinical anti-infective assets in its portfolio and is listed on the SIX Swiss Exchange (SIX: BSLN). More on basilea.com.

AMR Action Fund

The AMR Action Fund is the world’s largest public-private partnership investing in the development of new antimicrobial therapeutics.

Antimicrobial-resistant bacteria now kill nearly 1.3 million people a year, more than HIV/AIDS or malaria, and the loss of effective antibiotics threatens to undermine modern health care.

We invest in companies that are developing urgently needed therapeutics for priority pathogens and advocate for market reforms to change how society values these lifesaving drugs. Our aim is to help launch two to four new antimicrobials within the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges of our generation.



The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere.

PrecisionPhage Ltd

PrecisionPhage Ltd, a Finnish company founded upon two decades of phage research, features a large collection of phages and research services along with Phagenomics, a cutting-edge online platform for bacteriophage genome analysis. With our Phagenomics Software-as-a-Service, all DNA-sequence based phage analyses, annotations, phage product validations, genomic comparisons, phage cocktail designs and other steps in therapeutic use and academic research can be done by anyone. We are a comprehensive partner for research and development within the establishing phage ecosystem.

Shionogi & Co., Ltd.

Shionogi & Co., Ltd. is a 141-year-old global, research driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology.

For more information on Shionogi & Co., Ltd., please visit


Our dedication to public health is the thread that connects everything we do. 

It connects us to our history – since 1963, we have been fulfilling the vision of the Mérieux family to improve health, while maintaining the values of respect, accountability, transparency, and sharing.  Building on our strong legacy, we understand that our expertise in infectious diseases and our international presence give us a special duty to act as a responsible corporate citizen, serving the greater good and the community. ​ 

This commitment also connects us with our environment – infectious diseases are one of the major threats to human kind. Their emergence and spread are dramatically accelerated by climate change and globalization. The risk of finding ourselves unarmed to face ultra-resistant bacteria is now a reality. 

Diagnostics is a game changer in this fight. By pioneering diagnostic solutions, we help clinicians improve patient care and we help industries prevent contamination of the food and pharmaceuticals they produce. At bioMérieux we are convinced that, only by taking into account our entire ecosystem and the public interest, will we be able to succeed in building a healthier world and a more inclusive society. ​

We are bioMérieux.  We act for a positive impact.  We act for a healthier world.


At the German Center for Infection Research (DZIF), about 500 researchers from 35 institutions throughout Germany jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim of this nationwide collaboration between universities, hospitals and research institutions is to translate research results into clinical practice quickly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostic agents and drugs to treat infections.


Resistell AG is a clinical-stage company transforming the landscape of Antibiotic Susceptibility Testing (AST) with the world’s fastest AST platform based on proprietary nanomotion technology for measuring induced metabolic changes in living. Resistell Phenotech AST is a CE IVD certified rapid AST in bloodstream infections with a time-to-result of 4 hours. The 2nd generation device enabling an ultra-rapid AST of only 2 hours is already available. In addition to the diagnostic product, Resistell offers Phenotech Research, a globally available research device for exploring new applications.


Innovating Infection Diagnostics

InfectoGnostics is a public-private partnership that is breaking new grounds in infection diagnostics with over 30 collaborative partners. Partners at the research campus pioneer diagnostic methods to detect infectious agents and antibiotic resistance and aim for fast translation into of diagnostic products.

Visit our AMR 2024 booth with our partners Applyo, AID, Dynamic42, Fluidect, LEG Thuringia, and Leibniz Health Technologies. Together, we offer market-ready laboratory tools and point-of-care tests for human, veterinary, and environmental diagnostics. Committed to addressing the global threat of multi-resistant infectious agents, the goal of InfectoGnostics is to provide accurate diagnoses before therapies. Join us in advancing diagnostic innovation into effective solutions.

Aurobac Therapeutics

As a biopharma founded in 2022 by Boehringer Ingelheim, Evotec and bioMérieux, AUROBAC THERAPEUTICS ambitions to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.

We focus all our effort on identifying and developing innovative products with the ability to address clear unmet medical needs associated to bacterial infections and increasing AMR, aligned with viable clinical development plans based on a precision medicine concept.

We are currently seeking to strengthen our product portfolio and we are particularly interested in co-developing or in-licensing products targeting Gram-Negative ESKAPE pathogens for the treatment of Acute Respiratory Infections (HAP, VAP). 

Follow us on the web, X and LinkedIn

WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,850 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”


We provide excellent quality services in the early phases of drug discovery with the aim of generating new valuable leads. We develop customized cell-free and cell-based in-vitro assays covering a broad range of target classes, run high-throughput screening campaigns to identify hit compounds from both our high-quality compound collections (synthetic and natural) or those provided by our clients, using a variety of detection technologies, and support the hit-to-lead program of our clients to identify the most promising leads.

Thuringian ClusterManagement

LEG Thüringen® is a wholly owned subsidiary of the Free State of Thuringia with more than 250 employees. It supports companies in all phases of the location decision and the implementation of investment as well as research and development projects.

The Thuringian ClusterManagement (ThCM), a part of LEG Thüringen, fosters collaborations between companies, research and scientific institutions and strategically and conceptually contributes to the development of industry clusters in five pre-defined innovation fields. The interdisciplinary team works closely with the relevant stakeholders from business, academia, and intermediaries. In the health care sector, the ThCM keeps contact to various industry networks and the relevant stakeholders along the health care value chain and provides interfaces to other fields of technology development.

In Thuringia close cooperations between top research facilities and industry drives the development of rapid diagnostics and targeted anti-infection strategies to combat infectious diseases. This leads the way to develop and market effective strategies in this field including combinations of diagnostics and therapeutics.

Rime Bioinformatics

Rime Bioinformatics is a startup company focusing on helping phage projects putting their product on the market faster, through our regulation compliant, high-throughput phage DNA characterization technology.

A&J Science

A&J Science is a start-up pharmaceutical company located in S. Korea, established in 2021. Committed to combating antimicrobial resistance (AMR) and intractable bacterial related diseases, we are leveraging the full potential of unexploited natural product scaffolds that exhibit a novel mode of action through our medicinal chemistry platform technology. This platform technology enables expedited development of our pipelines in different indications, and our pre-clinical candidates possess distinctive advantages compared to the first-line of treatments. In the pursuit of scientific excellence, A&J science seeks to bridge innovations in the field of infectious diseases and global reinforcements towards new antibiotic development.

FiberCell Systems Inc.

FiberCell Systems Inc. is the supplier of hollow fiber bioreactors for the Hollow Fiber Infection Model (HFIM). The HFIM can precisely mimic human antibiotic in vivo bioavailability for the determination of optimum dosing profiles for maximum efficacy, reveal emerging resistance, total kill, and develop two and three drug combination therapies. It is closed, bio-safe, compact, and easy to use. The single use hollow fiber modules are produced under ISO 13485 for reliability and reproducibility. FiberCell Systems has over 20 years of experience putting the power of 3-D perfusion hollow fiber technology into your hands.

Bio-Connect is the EU distribution partner for FiberCell Systems Inc.



Symcel provides an assay tool for real-time biological activity measurements using isothermal microcalorimetry technology. Particularly suited for the development of antimicrobial compounds, coatings, and evaluating antimicrobial resistance.

The calScreener™, gives a phenotypic, metabolic readout in real-time. It directly measures the heat produced from metabolic processes, providing insights not previously possible with traditional methods. Measurements are sample independent meaning you can use product or process samples. Measure the kinetics of metabolism without any additional reagents.

LinkedIn: https://www.linkedin.com/company/symcel-sverige-ab
X (Twitter): https://twitter.com/symcel

Asymchem Inc.

Asymchem is a leading global CDMO known for its integrated offerings throughout the entire drug development lifecycle. From early-stage research to commercialization, we provide a tailored suite of services that cater to the specific needs of each project.

We are committed to embracing cutting-edge technologies that not only enhance efficiency and safety but also prioritize sustainability in the development and manufacturing process. This translates to smarter, greener, and more cost-effective solutions for our clients, ultimately speeding up the delivery of life-saving medications to patients.

Infex Therapeutics

Infex is a clinical-stage biotech R&D company that acquires, develops, and licenses innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new & novel therapies to meet the rising burden of critical priority infectious disease.

Based at Alderley Park in the UK, our work addresses unmet patient needs and will bring a new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

We have developed a flexible partnering model to progress these aims, so that treatments can be marketized quickly, and tackle the threat from AMR & other infectious diseases.

Email: info@infextx.com



LifeArc is a self-funded, not-for-profit medical research organisation and charity. They take science ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. LifeArc have been doing this for more than 25 years resulting in five licensed medicines.

LifeArc’s teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property. They bridge the gap between academic research and clinical development, providing funding, research and expert knowledge to translational science, all with a clear and unwavering commitment to having a positive impact on patient lives in areas of unmet medical need.  

Find out more: www.lifearc.org 

Adjuvant Capital

Adjuvant Capital is a Global Health Life Sciences Venture Capital Firm with presence in USA and Europe.

We have decades of experience in biopharmaceutical product development and invest in new interventions for historically overlooked and emerging indications. We relentlessly pursue meaningful, measurable public health impact in each investment, with an emphasis on UN SDG 3 (health and well-being for all)

Adjuvant’s investment portfolios are managed against industry-leading ESG and business integrity standards. These disease areas burden millions of patients worldwide and are the subject of significant public health tailwinds, creating investment opportunities uniquely accessible to the Adjuvant team.

Centre for Process Innovation Ltd (CPI)

CPI catalyses the adoption of advanced technologies and manufacturing solutions to benefit people, places, and our planet.

We’re a pioneering social enterprise that accelerates the development, scale-up and commercialisation of smart AgriFoodTech, energy storage, HealthTech, materials, and pharma innovations. Through our incredible innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future.

As a trusted partner of industry, academia, government, entrepreneurs and the investment community, we connect the dots within the innovation ecosystem to make great ideas and inventions a reality.

Epithelix Sàrl

Epithelix is Biotech Company, specialized in tissue engineering, leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. We provides in vitro alternatives to animal testing (NAMs).

Epithelix has developed a unique technology for long-term culture of fully primary in vitro human reconstituted tissues. The company commercialize ready-to-use nasal, tracheal, bronchi (MucilAir™), small-airways (SmallAir™) and alveolar (AlveolAir™) epithelia and advanced immunocompetent models integrating macrophages, neutrophils or dendritic cells.

Epithelix also provide testing services (CRO activity) offering a panel of assays to study airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases, Viral and Bacterial infections. A wide range of applications are available: toxicity assays, disease modelling, permeability of inhaled drugs, efficacy testing of novel antiviral or antimicrobial therapy, etc

Cerdak (Pty) Ltd

Cerdak is a non-medicated dressing with unique absorption and bacterial binding properties to physically remove and sequestrate bacteria from an open wound.  The dressing is made from inert micro-porous ceramics and therefor poses no risk for antimicrobial resistance.  Cerdak also owns a patent for sampling of wound flora with the porous ceramic for accurate identification of pathogens.  Cerdak was developed in South Africa and is used in both the prevention of infection and the treatment of wound infection.

BEAM Alliance

Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.

BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.

Swiss Biotech Association

The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.

Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley. Our +300 members represent the region’s triple helix and include universities, hospitals, human life science business, regional governments, selected municipalities and service providers. We create value for our members by co-hosting, launching and driving meetings, networks, seminars, conferences and projects, that strengthen the collaboration, networking and knowledge-sharing in the regions life science community, create critical mass and help realizing the full potential of Medicon Valley.

BIO Deutschland

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 380 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies. This committee comprehensively represents the various fields in the sector.

Life Science Austria (LISA)

Life Science Austria (LISA) promotes the life science sector in Austria on the international stage and is the first point of call for enquiries relating to it.  LISA is committed to the development, growth and prosperity of the Austrian life science industries as a leading component of the Austrian economy. On the international front, LISA also works towards Austria itself being a country known worldwide for the excellence of its life science sector.